Company Overview and News
KUALA LUMPUR (Aug 24): Evergreen Fibreboard Bhd's net profit nearly doubled to RM11.96 million or 1.41 sen a share in the second quarter ended June 30, 2018 (2QFY18), from RM6.2 million or 0.73 sen a share last year, contributed by foreign exchange (forex) gain, versus a forex loss.
BSMAF 5101 1818
KUALA LUMPUR (Aug 15): The FBM KLCI held on to its marginal gains at mid-morning today, despite the retreat at most regional markets, propped up by Petronas-linked stocks.
APEXF 5161 7090 0090 7192 8621 5681 JCYBF BATS 4162 7034 6033 5101 PNADF 3301 5797 6556 5819 PNAGF
KUALA LUMPUR (July 23): Interest in shares of export-oriented furniture manufacturers spiked, following news the United States is looking to impose a 10% tariff on more than 5,000 new Chinese imports worth US$200 billion, which includes furniture.
7006 7088 5101 LIIHF 5001
KUALA LUMPUR (July 23): The FBM KLCI dipped 0.24% at mid-morning today, tracking regional losses, weighed by select index-linked blue chips.
7172 UPBMF 7006 2089 5014 9334 6033 5101 LIIHF 7123 KLKBY 5238 2445 4588 PNADF 5738 7216 0026 MYPRY 2836 PNAGF
In the rubber glove sector, possible winners (but receiving only minimal spillover benefits) are Top Glove Corp Bhd, Hartalega Holdings Bhd and Kossan Rubber Industries Bhd.
TGLVY 7113 TPGVF 7006 7153 5168 7022 5101 GBTKF LIIHF HRGHY 5001
KUALA LUMPUR (July 11): Hong Leong IB Research has maintained its “Neutral” rating on the wood-based manufacturing sector and said that moving into 2H18, it believes that the sector will remain unfavourable as we opine that weaker ringgit alone is insufficient to mitigate the negative factors of (i) potential minimum wage hike and (ii) high rubber log wood prices.
KUALA LUMPUR: JF Apex expects Malayan Banking Bhd (Maybank), Pos Malaysia Bhd , Malaysia Building Sociey Bhd (MBSB), MMC Corp Bhd and CCM Duopharma to be among the stocks to watch on Wednesday following their latest quarterly results.
4634 1155 9385 3883 MLYBY 5209 MLYNF MGFCF 5101
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...